表紙
市場調査レポート

米国の再生医療市場 (2016-2020年)

Regenerative Medicine Market in the US 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 277867
出版日 ページ情報 英文 77 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
米国の再生医療市場 (2016-2020年) Regenerative Medicine Market in the US 2016-2020
出版日: 2015年12月23日 ページ情報: 英文 77 Pages
概要

再生医療は、ヒトの細胞、組織、または臓器の治療のために、治療用に誘発された、もしくは研究室で培養されたヒトの組織を利用するプロセスを扱っています。それは疾患や怪我を治療する媒体として、正常に機能していない、または損傷した細胞に代わる新たな細胞を生み出すのを手伝う、新たな治療の分野です。多様な疾患の治療における利用が期待されていることから、米国における再生医療市場は、2016-2020年の期間において驚異的なCAGR (複合年間成長率) 33%を超える伸びで成長することが見込まれています。

当レポートでは、米国の再生医療市場を取り上げ、遺伝子治療および市場の概要、パイプライン製品の状況、規制状況、市場発展促進要因、市場における課題、ならびにそれらの影響を概括し、製品別・用途別に市場の現状と見通しについて調査分析するとともに、主なベンダーのプロファイルをまとめています。

第1章 エグゼクティブサマリー

第2章 調査範囲

  • 市場概要
  • 主要ベンダーの製品提供

第3章 市場調査手法

  • 調査手法
  • 経済指標

第4章 イントロダクション

  • 市場の主な特徴

第5章 遺伝子治療:再生医療における新たな分野

第6章 パイプラインポートフォリオ

第7章 規制シナリオ

  • FDA (米食品医薬品局) の認可手順

第8章 市場情勢

  • 市場概要
  • 市場規模・予測
  • ファイブフォース分析

第9章 市場区分、製品別

  • 細胞治療
  • 米国の細胞治療市場
  • スキャホールド (足場)
  • 米国のスキャホールド (足場) 市場

第10章 市場区分、用途別

  • 皮膚科学
  • 筋骨格系
  • 眼球
  • 心血管

第11章 市場発展促進要因

  • 慢性疾患有病率の上昇
  • 技術革新
  • 研究開発活動への投資増

第12章 促進要因の影響

第13章 市場の課題

  • 厳しい規制認可手順
  • 倫理的課題
  • 臨床データの不足

第14章 促進要因と課題の影響

第15章 市場動向

  • パイプライン製品の増加
  • 戦略的アライアンス
  • 再生医療による医療コスト削減の可能性

第16章 ベンダー情勢

  • 競合シナリオ
  • 主なニュース
  • 合併・買収
  • 主要ベンダー分析、2015年
  • その他の主要なベンダー

第17章 主要ベンダーの分析

  • Acelity
  • Mesoblast
  • Organogenesis
  • Reprocell
  • Stryker

第18章 付録

  • 略語集

第19章 Technavioについて

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR7731

Market outlook of the regenerative medicine market in the US

Regenerative medicine deals with the process of using therapeutically-induced or laboratory grown human tissue to treat diseased or injured human cells, tissues, or organs. It is an emerging field of treatment that helps in producing new cells to substitute malfunctioning or injured cells as a vehicle to treat disease and injury. The regenerative medicine market can be characterized into three major modalities, namely tissue engineering, biomaterials/biomolecules, and stem cell therapy.

Technavio's market research analysts expect the regenerative medicine market in the US to grow at a fast pace, posting a remarkable CAGR of more than 33% during the forecast period because of the growing demand for tissue-engineered and stem cell products for the treatment of various diseases. The potential of these medicines in regenerating diseased organs is one of the major factors that drives the market in the US. The stem cells application and advancements in nanotechnology will further drive the progress in this market.

Segmentation by product and analysis of - cell therapy and scaffold

Cell therapy helps in treating the diseases or to improving the functioning of the existing cells, by administrating of cells into the body. This therapy addresses medical conditions related to the bone, cartilage, heart, skin, digestive system, reproductive system, eye, blood, spine, brain, and the nervous system. In 2015, cell therapy segment accounted for approximately 80% of the market share.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

  • Cell therapy
  • Scaffold

Segmentation by application and analysis of - dermatology, musculoskeletal, ocular, and cardiovascular

The year 2015 saw the precedence of the dermatology segment, accounting for a market share of more than 51%. Dermatology includes the treatment of burns and chronic wounds that requires a quick response, and skin grafting is essential in many cases. Factors such as the increase in obesity and diabetes, growing elderly population, and an increase in life expectancy are some of the causes contributing to the growth of the dermatology market.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

  • Dermatology
  • Musculoskeletal
  • Ocular
  • Cardiovascular

Competitive landscape and key vendors - AkzoNobel, Jotun, PPG

Regenerative medicine market in the US is highly competitive and fragmented because of the presence of several established vendors and this competitive environment is expected to intensify with advances in R&D and technological innovations. International players are likely to acquire regional or local players to enhance their products and expand their market share during the forecast period.

The top vendors in the market are -

  • Acelity
  • Mesoblast
  • Organogenesis
  • Reprocell
  • Stryker

Other prominent vendors include Aastrom Biosciences, Acologix, AlloCure, Allosource, Alphatec Spine, Altrika, Amorcyte, Argos Therapeutics, Athersys, Avita Medical, Axogen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, BioLife Solutions, BioRestorative Therapies, BioTissue Technologies, Bluebird Bio, BrainStorm Cell Therapeutics, Calimmune, Capricor, Celyad (Cardio3 BioSciences), Cell Medica, Cesca, CryoLife, Cynata Therapeutics, Cytori, Cytori Therapeutics, Dendreon, DiscGenics, Fate Therapeutics, Fibrocell, Fibrocell Science, Forticell Bioscience, Fortress Biotech, Gamida Cell, Geron, Harvard Apparatus Regenerative Technology, Healthpoint, Histogen, Histogenics, Humacyte, Immunocellular Therapeutics P, Integra Life Sciences, Intercytex, InVivo Therapeutics, iSTO Technologies, Juventas Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, Living Cell Technologies, MaxCyte, Medtronics, Mesoblast, MiMedix Group, Nanofiber Solutions CTO, Nanotope, Neuralstem, Newlink Genetics, Northwest Biotherapeutics, NovaRx, Ocata Therapeutics, Opexa , Therapeutics, Organovo Holdings, Orteq, Orthofix, Osiris Therapeutics, Osteotech, Pfizer, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, RhinoCyte, RTI Surgical, SanBio, Sangamo, Shire Regenerative Medicine, StemCells, Stratatech, TEI Biosciences, Tengion, Thermo Fischer Scientific, TiGenix, Tissue Genesis, TissueGene, VentriNova, Vericel, ViaCyte, Vistagen, and Zimmer.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the regenerative medicine market in the US?
  • What are the key market trends impacting the growth of the regenerative medicine market in the US?
  • What are the challenges to market growth?
  • Who are the key vendors in the regenerative medicine market in the US?
  • What are the market opportunities and threats faced by the vendors in the regenerative medicine market in the US?
  • What are the key outcomes of the five forces analysis of the regenerative medicine market in the US?

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Gene therapy: An emerging field in regenerative medicine

PART 06: Pipeline portfolio

PART 07: Regulatory scenario

  • FDA process

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by product

  • Cell therapy
  • Cell therapy market in US
  • Scaffold
  • Scaffold market in US

PART 10: Market segmentation by application

  • Dermatology
  • Musculoskeletal
  • Ocular
  • Cardiovascular

PART 11: Market drivers

  • Rise in prevalence of chronic diseases
  • Technological innovations
  • Increase in investment for research and development activities

PART 12: Impact of drivers

PART 13: Market challenges

  • Stringent regulatory approval process
  • Ethical challenges
  • Lack of clinical data

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Increase in pipeline products
  • Strategic alliances
  • Potential of regenerative medicine toward decreasing healthcare costs

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Key vendor analysis 2015
  • Other prominent vendors

PART 17: Key vendor analysis

  • Acelity
  • Mesoblast
  • Organogenesis
  • Reprocell
  • Stryker

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Number of ongoing clinical trials
  • Exhibit 03: Gene therapy pipeline products based on indication
  • Exhibit 04: Gene therapy research by sponsorship
  • Exhibit 05: Some of the pipeline products of gene therapy
  • Exhibit 06: Pipeline products of regenerative medicine for cardiovascular diseases
  • Exhibit 07: Pipeline products of regenerative medicine for central nervous system diseases
  • Exhibit 08: Pipeline products of regenerative medicine for spine and orthopedics diseases
  • Exhibit 09: Pipeline products of regenerative medicine for diabetes and autoimmune diseases
  • Exhibit 10: Overview of number of companies and products of regenerative medicine
  • Exhibit 11: Financial performance of regenerative medicine 2013 and 2014
  • Exhibit 12: Marketed products of different therapy areas in 2014
  • Exhibit 13: Regenerative medicine stakeholders
  • Exhibit 14: Guidelines to be followed prior to the initiation of clinical studies for regenerative products
  • Exhibit 15: Regenerative medicine market in US 2015-2020 ($ millions)
  • Exhibit 16: Five forces analysis
  • Exhibit 17: Cell therapy procedure
  • Exhibit 18: Cell therapy market in US 2015-2020 ($ millions)
  • Exhibit 19: Scaffold market in US 2015-2020 ($ millions)
  • Exhibit 20: Segmentation of regenerative medicine market in US 2015-2020 ($ millions)
  • Exhibit 21: Segmentation of regenerative medicine market in US 2015-2020
  • Exhibit 22: Segmentation of regenerative medicine by application 2015
  • Exhibit 23: Revenues funded by federal agencies for regenerative medicine research
  • Exhibit 24: Impact of drivers
  • Exhibit 25: Impact of drivers and challenges
  • Exhibit 26: Some of the mid- and late-stage pipeline products for regenerative medicine
  • Exhibit 27: Mesoblast: Key takeaways
  • Exhibit 28: Reprocell: Key takeaways
  • Exhibit 29: Acelity: Key takeaways
  • Exhibit 30: Organogenesis: Key takeaways
  • Exhibit 31: Stryker: Key takeaways
  • Exhibit 32: Acelity: Business segmentation by revenue 2014
  • Exhibit 33: Acelity: Business segmentation by revenue 2013 and 2014
  • Exhibit 34: Acelity: Geographical segmentation by revenue 2014
  • Exhibit 35: Mesoblast: Product pipeline
  • Exhibit 36: Organogenesis: Product offerings
  • Exhibit 37: Reprocell: Product categories
  • Exhibit 38: Stryker: Business/product segmentation by revenue 2014
  • Exhibit 39: Stryker: Business segmentation by revenue 2013 and 2014 ($ millions)
Back to Top